<DOC>
	<DOCNO>NCT01096121</DOCNO>
	<brief_summary>Patients sickle cell anaemia may develop renal disease . In fact , renal disease occur 40 % adults patient ( macroalbuminuria ) evolution end-stage renal disease half . Microalbuminuria early sensitive marker glomerular damage . It appear first decade occur 20 25 % infant ( 2 18 year ) . Physiopathology renal scarring well understood actually . Renal scarring might due glomerular hyperfiltration vascular endothelial damage . Angiotensin-converting enzyme inhibitor ( ACE ) study use diabetic nephropathy . In study 26 sickle cell adult , albuminuria reduce 50 % ACE compare placebo six month treatment . It might interest study ACE efficacy sickle cell child microalbuminuria renal disease directly relate sickle cell influence cardiovascular risk factor like adult patient . We hypothesize successful ACE treatment 40 % case nine month treatment period . A success define 50 % reduction albuminuria/creatinuria ratio .</brief_summary>
	<brief_title>Angiotensin-converting Enzyme Inhibitors Early Sickle Cell Renal Disease Children</brief_title>
	<detailed_description>This multicenter study . In order include 72 patient pre-include 400 patient . They include study sign protocol consent . For final inclusion study , two albuminuria/creatinuria ratio equal 3mg/mmol . If , inclusion do patient randomize ( placebo/enalapril ) CLEANWEB software . A blood sample do . Treatment tolerance check day 7 ( blood sample renal tolerance clinical examination ) , month 1 ( clinical examination ) , month 3 ( clinical examination ) , month 6 ( clinical examination ) , month 9 ( clinical examination ) . Treatment efficacy evaluate albuminuria/creatinuria ratio month 1 , month 3 , month 6 , month 9 . Physiopathology ACE efficacy study first day month 9 dosage ICAM-1 VCAM-1 . Treatment plain posology ( 0.5mg/kg/day ) progressively obtain three month period , begin 0.2mg/kg/day .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Sickle cell disease ( SS , SC , Sb thalassemia , SD Punjab ) Affiliation French Health benefit Signed informed consent Albuminemia / Creatinemia &gt; = 3 mg / mmol ( 2 sample ) Albuminemia / Creatinemia &gt; 100 mg / mmol Hypersensibility enalapril Angiooedemas due previous treatment ACE idiopathic hereditary angiooedemas cerebral echodoppler treatment lithium digoxine treatment ACE congenital galactosemia Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Angiotensin-converting enzyme inhibitor ( ACE )</keyword>
	<keyword>Renal disease</keyword>
	<keyword>Microalbuminemia</keyword>
</DOC>